# A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)

> **NCT00210080** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 700 (—)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Uridine 5'-Triphosphate (UTP) Solution for Inhalation

## Key facts

- **NCT ID:** NCT00210080
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** 700 (—)
- **Last updated:** 2015-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00210080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00210080, "A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00210080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*